Legacy Private Trust’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-10,240
Closed -$1.15M 245
2021
Q4
$1.15M Sell
10,240
-700
-6% -$84.4K 0.09% 144
2021
Q3
$1.38M Sell
10,940
-855
-7% -$110K 0.11% 129
2021
Q2
$1.6M Sell
11,795
-3,855
-25% -$507K 0.13% 123
2021
Q1
$2.12M Buy
15,650
+840
+6% +$126K 0.19% 98
2020
Q4
$2.08M Sell
14,810
-390
-3% -$50K 0.2% 99
2020
Q3
$1.69M Buy
15,200
+340
+2% +$38.1K 0.18% 99
2020
Q2
$1.66M Buy
+14,860
New +$1.46M 0.18% 97

Other funds holding XBI

Legacy Private Trust's XBI Position: Q1 2022 in Review

Legacy Private Trust sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2022, closing a stake of 10,240 shares — an estimated $1.15M sold.

Legacy Private Trust first reported a position in XBI in Q2 2020 and held it in 7 quarters. The position peaked at $2.12M in Q1 2021. 702 funds tracked by Wall St. Rank hold XBI as of Q1 2022.

  • Legacy Private Trust reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2022 after selling out during the quarter.
  • Legacy Private Trust sold 10,240 State Street SPDR S&P Biotech ETF shares in Q1 2022, an estimated $1.15M.
  • Legacy Private Trust first reported a position in State Street SPDR S&P Biotech ETF in Q2 2020 and held it in 7 quarters.
  • Legacy Private Trust's State Street SPDR S&P Biotech ETF position peaked at $2.12M in Q1 2021.
  • 702 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2022.

Based on Legacy Private Trust's 13F filing for Q1 2022, filed 11 Apr 2022.